As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating auotimmune diseases with significant unmet patient needs. Our investigational products batoclimab (“IMVT-1401”) and IMVT-1402 are novel, fully human, monoclonal antibodies targeting the FcRn receptor. Both assets are in development as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
All Other Basic Organic Chemical Manufacturing (325199)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
Immunovant, Inc.
Chau Cheng, PhD, MBA
Investor Relations
info@immunovant.com
Company Contact
Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018